CN1583795A - 长效的人干扰素类似物 - Google Patents
长效的人干扰素类似物 Download PDFInfo
- Publication number
- CN1583795A CN1583795A CN 200410042814 CN200410042814A CN1583795A CN 1583795 A CN1583795 A CN 1583795A CN 200410042814 CN200410042814 CN 200410042814 CN 200410042814 A CN200410042814 A CN 200410042814A CN 1583795 A CN1583795 A CN 1583795A
- Authority
- CN
- China
- Prior art keywords
- leu
- glu
- interferon
- lys
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010050904 Interferons Proteins 0.000 title claims abstract description 281
- 102000014150 Interferons Human genes 0.000 title claims abstract description 280
- 229940079322 interferon Drugs 0.000 title claims abstract description 279
- 241000282414 Homo sapiens Species 0.000 title abstract description 75
- 230000004071 biological effect Effects 0.000 title abstract description 14
- 230000005923 long-lasting effect Effects 0.000 title abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 110
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 60
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 59
- 108010088751 Albumins Proteins 0.000 claims abstract description 45
- 102000009027 Albumins Human genes 0.000 claims abstract description 44
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 125
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 111
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 79
- 102000004169 proteins and genes Human genes 0.000 claims description 67
- 235000018102 proteins Nutrition 0.000 claims description 63
- 239000002773 nucleotide Substances 0.000 claims description 62
- 125000003729 nucleotide group Chemical group 0.000 claims description 62
- 241000235648 Pichia Species 0.000 claims description 43
- 241000894006 Bacteria Species 0.000 claims description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 102000007562 Serum Albumin Human genes 0.000 claims description 14
- 108010071390 Serum Albumin Proteins 0.000 claims description 14
- 102000004889 Interleukin-6 Human genes 0.000 claims description 11
- 108090001005 Interleukin-6 Proteins 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 11
- 102000000588 Interleukin-2 Human genes 0.000 claims description 10
- 108010002350 Interleukin-2 Proteins 0.000 claims description 10
- 108020001507 fusion proteins Proteins 0.000 claims description 10
- 102000037865 fusion proteins Human genes 0.000 claims description 8
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 6
- 241000196324 Embryophyta Species 0.000 claims description 5
- 102100040018 Interferon alpha-2 Human genes 0.000 claims description 5
- 238000010361 transduction Methods 0.000 claims description 5
- 230000026683 transduction Effects 0.000 claims description 5
- 241000238631 Hexapoda Species 0.000 claims description 4
- 229940100601 interleukin-6 Drugs 0.000 claims description 4
- 238000001890 transfection Methods 0.000 claims description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 241000235036 Debaryomyces hansenii Species 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 101001034829 Homo sapiens Interferon alpha-10 Proteins 0.000 claims 1
- 101001034828 Homo sapiens Interferon alpha-14 Proteins 0.000 claims 1
- 101001034835 Homo sapiens Interferon alpha-16 Proteins 0.000 claims 1
- 101001034833 Homo sapiens Interferon alpha-21 Proteins 0.000 claims 1
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 claims 1
- 102100039734 Interferon alpha-10 Human genes 0.000 claims 1
- 102100039733 Interferon alpha-14 Human genes 0.000 claims 1
- 102100039728 Interferon alpha-16 Human genes 0.000 claims 1
- 102100039730 Interferon alpha-17 Human genes 0.000 claims 1
- 101710106876 Interferon alpha-17 Proteins 0.000 claims 1
- 108010078049 Interferon alpha-2 Proteins 0.000 claims 1
- 102100039729 Interferon alpha-21 Human genes 0.000 claims 1
- 102100039949 Interferon alpha-4 Human genes 0.000 claims 1
- 101710127458 Interferon alpha-4 Proteins 0.000 claims 1
- 102100039948 Interferon alpha-5 Human genes 0.000 claims 1
- 101710127457 Interferon alpha-5 Proteins 0.000 claims 1
- 102100040007 Interferon alpha-6 Human genes 0.000 claims 1
- 101710127460 Interferon alpha-6 Proteins 0.000 claims 1
- 102100039350 Interferon alpha-7 Human genes 0.000 claims 1
- 101710127459 Interferon alpha-7 Proteins 0.000 claims 1
- 102100036532 Interferon alpha-8 Human genes 0.000 claims 1
- 102100026688 Interferon epsilon Human genes 0.000 claims 1
- 101710147309 Interferon epsilon Proteins 0.000 claims 1
- 102100020990 Interferon lambda-1 Human genes 0.000 claims 1
- 102100020989 Interferon lambda-2 Human genes 0.000 claims 1
- 101710099622 Interferon lambda-2 Proteins 0.000 claims 1
- 101000999348 Mus musculus Interferon alpha-12 Proteins 0.000 claims 1
- 101000999357 Mus musculus Interferon alpha-13 Proteins 0.000 claims 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 claims 1
- 108010047126 interferon-alpha 8 Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 238000002360 preparation method Methods 0.000 abstract description 14
- 230000006798 recombination Effects 0.000 abstract description 12
- 238000005215 recombination Methods 0.000 abstract description 12
- 238000002474 experimental method Methods 0.000 abstract description 10
- 241001465754 Metazoa Species 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 238000003860 storage Methods 0.000 abstract description 7
- 208000006454 hepatitis Diseases 0.000 abstract description 5
- 208000015181 infectious disease Diseases 0.000 abstract description 5
- 230000002035 prolonged effect Effects 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 3
- 230000002155 anti-virotic effect Effects 0.000 abstract description 3
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 abstract description 2
- 238000012407 engineering method Methods 0.000 abstract description 2
- 208000032839 leukemia Diseases 0.000 abstract description 2
- 231100000283 hepatitis Toxicity 0.000 abstract 3
- 208000030507 AIDS Diseases 0.000 abstract 1
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 230000001018 virulence Effects 0.000 abstract 1
- 102220023258 rs387907548 Human genes 0.000 description 61
- 230000004927 fusion Effects 0.000 description 50
- 210000004027 cell Anatomy 0.000 description 47
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 238000000034 method Methods 0.000 description 35
- 239000013612 plasmid Substances 0.000 description 33
- 102220369447 c.1352G>A Human genes 0.000 description 28
- 108090000467 Interferon-beta Proteins 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 25
- 108010047761 Interferon-alpha Proteins 0.000 description 23
- 102000006992 Interferon-alpha Human genes 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- 108010025188 Alcohol oxidase Proteins 0.000 description 19
- 102000003996 Interferon-beta Human genes 0.000 description 19
- 239000013598 vector Substances 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- 210000002381 plasma Anatomy 0.000 description 17
- 238000003752 polymerase chain reaction Methods 0.000 description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 description 15
- 229960001388 interferon-beta Drugs 0.000 description 15
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 14
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 235000015097 nutrients Nutrition 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 13
- 230000009385 viral infection Effects 0.000 description 13
- 230000000840 anti-viral effect Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 102220023257 rs387907546 Human genes 0.000 description 11
- 101150061183 AOX1 gene Proteins 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 238000001502 gel electrophoresis Methods 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 8
- 102220369446 c.1274G>A Human genes 0.000 description 8
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 8
- 208000002672 hepatitis B Diseases 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 102100026720 Interferon beta Human genes 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000008827 biological function Effects 0.000 description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 7
- 230000035800 maturation Effects 0.000 description 7
- 238000010369 molecular cloning Methods 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000008521 reorganization Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 241000233866 Fungi Species 0.000 description 5
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 108010062065 albumin interferon Proteins 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 101150026546 hsa gene Proteins 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 108010045648 interferon omega 1 Proteins 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 208000005176 Hepatitis C Diseases 0.000 description 4
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 4
- 241000235649 Kluyveromyces Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 102220369445 c.668T>C Human genes 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 102000043557 human IFNG Human genes 0.000 description 4
- 108010002492 human interferon alfa-1b Proteins 0.000 description 4
- 102000000707 human interferon alfa-1b Human genes 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 102220023256 rs387907547 Human genes 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 102000002265 Human Growth Hormone Human genes 0.000 description 3
- 108010000521 Human Growth Hormone Proteins 0.000 description 3
- 239000000854 Human Growth Hormone Substances 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 108010079944 Interferon-alpha2b Proteins 0.000 description 3
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 3
- 108091008109 Pseudogenes Proteins 0.000 description 3
- 102000057361 Pseudogenes Human genes 0.000 description 3
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- 101150006240 AOX2 gene Proteins 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 2
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 101710173438 Late L2 mu core protein Proteins 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 241001123227 Saccharomyces pastorianus Species 0.000 description 2
- 241000235346 Schizosaccharomyces Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000003677 hemocyte Anatomy 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 208000018191 liver inflammation Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- -1 rabbit-ω Proteins 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 102220004457 rs11567847 Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 1
- FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- QRBLKGHRWFGINE-UGWAGOLRSA-N 2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2s,3r,4r,5s)-4-carbamoyl-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)- Chemical compound N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(C)=O)NC(=O)C(C)C(O)C(C)NC(=O)C(C(O[C@H]1[C@@]([C@@H](O)[C@H](O)[C@H](CO)O1)(C)O[C@H]1[C@@H]([C@](O)([C@@H](O)C(CO)O1)C(N)=O)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C QRBLKGHRWFGINE-UGWAGOLRSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101150078509 ADH2 gene Proteins 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 101150021974 Adh1 gene Proteins 0.000 description 1
- 101710134784 Agnoprotein Proteins 0.000 description 1
- 102100034035 Alcohol dehydrogenase 1A Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 102000003916 Arrestin Human genes 0.000 description 1
- 108090000328 Arrestin Proteins 0.000 description 1
- 241000893451 Arthroderma Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 241001508787 Citeromyces Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000235035 Debaryomyces Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 108010001498 Galectin 1 Proteins 0.000 description 1
- 102100021736 Galectin-1 Human genes 0.000 description 1
- 102100024637 Galectin-10 Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101001011019 Gallus gallus Gallinacin-10 Proteins 0.000 description 1
- 101001011021 Gallus gallus Gallinacin-12 Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101150069554 HIS4 gene Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- LTQCLFMNABRKSH-UHFFFAOYSA-N Phleomycin Natural products N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C LTQCLFMNABRKSH-UHFFFAOYSA-N 0.000 description 1
- 108010035235 Phleomycins Proteins 0.000 description 1
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 101710124584 Probable DNA-binding protein Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 101710188306 Protein Y Proteins 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000223252 Rhodotorula Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000235003 Saccharomycopsis Species 0.000 description 1
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 101150006914 TRP1 gene Proteins 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000157 blood function Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000009519 fu-yuan Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000009655 industrial fermentation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000012966 insertion method Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000590 parasiticidal effect Effects 0.000 description 1
- 239000002297 parasiticide Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (10)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48398403P | 2003-06-30 | 2003-06-30 | |
US60/483,984 | 2003-07-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1583795A true CN1583795A (zh) | 2005-02-23 |
CN1269840C CN1269840C (zh) | 2006-08-16 |
Family
ID=34619282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410042814 Expired - Lifetime CN1269840C (zh) | 2003-06-30 | 2004-05-26 | 长效的人干扰素类似物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1269840C (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100385003C (zh) * | 2006-01-13 | 2008-04-30 | 杭州九源基因工程有限公司 | 重组人血清白蛋白-干扰素α2b 融合蛋白的生产方法 |
CN101768601A (zh) * | 2010-02-01 | 2010-07-07 | 山东泉港药业有限公司 | 一种重组人血白蛋白—干扰素α2b的生产方法 |
CN1896106B (zh) * | 2006-02-07 | 2011-09-14 | 上海欣百诺生物科技有限公司 | 一种人血清白蛋白融合长效干扰素制备工艺 |
CN102199208A (zh) * | 2011-01-28 | 2011-09-28 | 武汉吉天朋生物科技发展有限公司 | 一种通用的载药系统及制备方法 |
CN102757502A (zh) * | 2011-04-27 | 2012-10-31 | 中国医学科学院病原生物学研究所 | 一种融合人白细胞介素28b及其制备方法 |
CN101665798B (zh) * | 2008-09-06 | 2012-11-21 | 浙江我武生物科技股份有限公司 | 一种制备重组人血清白蛋白与干扰素α融合蛋白的方法 |
CN101391103B (zh) * | 2008-07-31 | 2013-07-24 | 张可 | 一种预防和治疗艾滋病病毒感染的药物组合物 |
CN105777908A (zh) * | 2007-06-06 | 2016-07-20 | 天津林达生物科技有限公司 | 重组人血清白蛋白/角质细胞生长因子融合蛋白 |
CN109381698A (zh) * | 2017-08-06 | 2019-02-26 | 复旦大学 | 人α干扰素亚型在制备抗乙型肝炎病毒药物中的用途 |
CN109627343A (zh) * | 2018-12-27 | 2019-04-16 | 北京美福源生物医药科技有限公司 | 长效细胞因子基因衍生物融合蛋白 |
CN114835795A (zh) * | 2015-11-16 | 2022-08-02 | Ubi蛋白公司 | 用于延长蛋白质半衰期的方法 |
-
2004
- 2004-05-26 CN CN 200410042814 patent/CN1269840C/zh not_active Expired - Lifetime
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100385003C (zh) * | 2006-01-13 | 2008-04-30 | 杭州九源基因工程有限公司 | 重组人血清白蛋白-干扰素α2b 融合蛋白的生产方法 |
CN1896106B (zh) * | 2006-02-07 | 2011-09-14 | 上海欣百诺生物科技有限公司 | 一种人血清白蛋白融合长效干扰素制备工艺 |
CN105777908B (zh) * | 2007-06-06 | 2020-03-27 | 天津林达生物科技有限公司 | 重组人血清白蛋白/角质细胞生长因子融合蛋白 |
CN105777908A (zh) * | 2007-06-06 | 2016-07-20 | 天津林达生物科技有限公司 | 重组人血清白蛋白/角质细胞生长因子融合蛋白 |
CN101391103B (zh) * | 2008-07-31 | 2013-07-24 | 张可 | 一种预防和治疗艾滋病病毒感染的药物组合物 |
CN101665798B (zh) * | 2008-09-06 | 2012-11-21 | 浙江我武生物科技股份有限公司 | 一种制备重组人血清白蛋白与干扰素α融合蛋白的方法 |
CN101768601B (zh) * | 2010-02-01 | 2013-08-07 | 山东泉港药业有限公司 | 一种重组人血白蛋白—干扰素α2b的生产方法 |
CN101768601A (zh) * | 2010-02-01 | 2010-07-07 | 山东泉港药业有限公司 | 一种重组人血白蛋白—干扰素α2b的生产方法 |
CN102199208A (zh) * | 2011-01-28 | 2011-09-28 | 武汉吉天朋生物科技发展有限公司 | 一种通用的载药系统及制备方法 |
CN102199208B (zh) * | 2011-01-28 | 2013-06-05 | 武汉吉天朋生物科技发展有限公司 | 一种通用的载药系统及制备方法 |
CN102757502A (zh) * | 2011-04-27 | 2012-10-31 | 中国医学科学院病原生物学研究所 | 一种融合人白细胞介素28b及其制备方法 |
CN114835795A (zh) * | 2015-11-16 | 2022-08-02 | Ubi蛋白公司 | 用于延长蛋白质半衰期的方法 |
CN109381698A (zh) * | 2017-08-06 | 2019-02-26 | 复旦大学 | 人α干扰素亚型在制备抗乙型肝炎病毒药物中的用途 |
CN109627343A (zh) * | 2018-12-27 | 2019-04-16 | 北京美福源生物医药科技有限公司 | 长效细胞因子基因衍生物融合蛋白 |
Also Published As
Publication number | Publication date |
---|---|
CN1269840C (zh) | 2006-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1142996C (zh) | 稳定的杀菌/增强通透性蛋白质产物及其药用组合物 | |
CN1240717C (zh) | 低毒性的人干扰素-α类似物 | |
CN1279718A (zh) | 包含HIV-1Tat和/或Nef蛋白的融合蛋白 | |
CN1269840C (zh) | 长效的人干扰素类似物 | |
CN1515672A (zh) | 人类趋化因子β-8,趋化因子β-1和巨噬细胞炎性蛋白-4 | |
CN1221452A (zh) | 杂合干扰素组合物及其使用方法 | |
CN1241638C (zh) | Ifnar2/ifn复合物 | |
CN1090510A (zh) | 干扰素-τ组成物及其用途 | |
CN1568369A (zh) | 杂合的干扰素/干扰素Tau蛋白、组合物和使用方法 | |
CN101045156A (zh) | 特异靶向性药物及其用途 | |
CN1357042A (zh) | 白介素-17相关哺乳动物细胞因子、编码其的多核苷酸、应用 | |
CN1309423C (zh) | 干扰素γ偶联物 | |
CN1257186C (zh) | 干扰素γ多肽变体 | |
CN1161468C (zh) | Mpl配体类似物 | |
CN1553955A (zh) | 血小板糖蛋白IBα融合多肽和其利用的方法 | |
CN1256347C (zh) | 激肽原第五结构域-肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途 | |
CN1823090A (zh) | 血小板糖蛋白IB-α变体融合多肽及其用法 | |
CN1187447C (zh) | Mpl配体类似物 | |
CN1896104A (zh) | 细胞抑制因子与白蛋白的融合蛋白 | |
CN1626554A (zh) | 人血清白蛋白与白细胞介素2的融合蛋白及其编码基因 | |
CN1781933A (zh) | 胸腺素α1活性片段环肽类似物及其聚乙二醇化衍生物 | |
CN1684979A (zh) | 糖基化的人干扰素α同种型 | |
CN1257187C (zh) | 钙网蛋白-肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途 | |
CN1220702C (zh) | 促胰岛素分泌肽及其用途 | |
CN1200097C (zh) | 重组人表皮生长因子、其制备方法和药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TIANJIN BOYING BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: U. S. FUYUAN GROUP Effective date: 20070420 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20070420 Address after: 300457 China TEDA economic and Technological Development Zone, Tianjin, international entrepreneurship center, 10 floor Patentee after: TIANJIN SINOBIOTECH LTD. Address before: California, USA Patentee before: U S FUYUAN Group |
|
ASS | Succession or assignment of patent right |
Owner name: BEIJING MEIFUYUAN BIOMEDICAL TECHNOLOGY CO., LTD. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20100423 Address after: 300457 China TEDA economic and Technological Development Zone, Tianjin, international entrepreneurship center, 10 floor Patentee after: TIANJIN SINOBIOTECH LTD. Patentee after: BEIJING MEIFUYUAN BIOMEDICAL TECHNOLOGY CO.,LTD. Address before: 300457 China TEDA economic and Technological Development Zone, Tianjin, international entrepreneurship center, 10 floor Patentee before: TIANJIN SINOBIOTECH LTD. |
|
ASS | Succession or assignment of patent right |
Owner name: ZHONGMEI FUYUAN BIOTECHNOLOGY (BEIJING) CO., LTD. Free format text: FORMER OWNER: TIANJIN SINO BIOTECHNOLOGY LTD., FORTUNEROCK INC. Effective date: 20130608 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 300000 BINHAI NEW ZONE, TIANJIN CITY TO: 100125 CHAOYANG, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130608 Address after: 100125 Beijing Chaoyang District xiaoyunli Street Xiaoyun center building A room 1602 Patentee after: Fortunerock (China) Co.,Ltd. Patentee after: BEIJING MEIFUYUAN BIOMEDICAL TECHNOLOGY CO.,LTD. Address before: 300000, Tianjin TEDA economic and Technological Development Zone, international entrepreneurship center, 10 floor Patentee before: TIANJIN SINOBIOTECH LTD. Patentee before: BEIJING MEIFUYUAN BIOMEDICAL TECHNOLOGY CO.,LTD. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 100125 Beijing Chaoyang District xiaoyunli Street Xiaoyun center building A room 1602 Co-patentee after: BEIJING MEIFUYUAN BIOMEDICAL TECHNOLOGY Co.,Ltd. Patentee after: FORTUNEROCK BIOTECHNOLOGY (BEIJING) Co.,Ltd. Address before: 100125 Beijing Chaoyang District xiaoyunli Street Xiaoyun center building A room 1602 Co-patentee before: BEIJING MEIFUYUAN BIOMEDICAL TECHNOLOGY Co.,Ltd. Patentee before: Fortunerock (China) Co.,Ltd. |
|
PP01 | Preservation of patent right | ||
PP01 | Preservation of patent right |
Effective date of registration: 20220321 Granted publication date: 20060816 |
|
PD01 | Discharge of preservation of patent | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20220926 Granted publication date: 20060816 |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 100125 room 1602, block a, Xiaoyun center building, xiaoyunli South Street, Chaoyang District, Beijing Patentee after: Fortune Rock (China) Co.,Ltd. Patentee after: BEIJING MEIFUYUAN BIOMEDICAL TECHNOLOGY CO.,LTD. Address before: 100125 room 1602, block a, Xiaoyun center building, xiaoyunli South Street, Chaoyang District, Beijing Patentee before: FORTUNEROCK BIOTECHNOLOGY (BEIJING) Co.,Ltd. Patentee before: BEIJING MEIFUYUAN BIOMEDICAL TECHNOLOGY CO.,LTD. |
|
CX01 | Expiry of patent term |
Granted publication date: 20060816 |
|
CX01 | Expiry of patent term |